US2017313664A1PendingUtilityA1

Novel form of pyrimidine compound having dibenzylamine structure

49
Assignee: KOWA COPriority: May 31, 2013Filed: May 15, 2017Published: Nov 2, 2017
Est. expiryMay 31, 2033(~6.9 yrs left)· nominal 20-yr term from priority
Inventors:Koichi YamazakiKennosuke MatsudaTaichi KusakabeTadaaki OhgiyaKimiyuki Shibuya
C07D 239/47A61P 3/06C07B 2200/13
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

It is an object of the present invention to provide a novel form of (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid, which is useful for preventing and/or treating diseases such as dyslipidemia. (S)-trans-{4-[({2-[({1-[3,5-bis(Trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid hydrochloride.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A crystal of (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methyl-sulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid hydrochloride. 
     
     
         2 . The crystal according to  claim 1 , wherein the hydrochloride is a monohydrochloride. 
     
     
         3 . The crystal according to  claim 1 , which has excellent heat stability. 
     
     
         4 . A pharmaceutical composition comprising the crystal according to  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         5 . A method for producing a pharmaceutical composition, comprising a step of mixing the crystal according to  claim 1  with a pharmaceutically acceptable carrier. 
     
     
         6 . A pharmaceutical composition comprising the crystal according to  claim 2  and a pharmaceutically acceptable carrier. 
     
     
         7 . A method for producing a pharmaceutical composition, comprising a step of mixing the crystal according to  claim 2  with a pharmaceutically acceptable carrier. 
     
     
         8 . A pharmaceutical composition comprising the crystal according to  claim 3  and a pharmaceutically acceptable carrier. 
     
     
         9 . A method for producing a pharmaceutical composition, comprising a step of mixing the crystal according to  claim 3  with a pharmaceutically acceptable carrier. 
     
     
         10 . The crystal according to  claim 2 , which has excellent heat stability.

Join the waitlist — get patent alerts

Track US2017313664A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.